The iCares bandage integrates advanced biosensors and AI to monitor chronic wounds, offering proactive care and early warning ...

The global Digital Wound Management Devices Market was valued at USD 2,415.89 million in 2024 and is projected to reach USD 3 ...

Humans heal skin injuries significantly more slowly than certain primates. Evolutionary changes may explain the trade-off.

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering ...

This award will support research led by Suresh Thallapuranam, in collaboration with Kyle Quinn and Narasimhan Rajaram from the Department of Biomedical Engineering, along with Jingyi Chen from the ...

Recognized for Advancing Global Wound Care Through Innovation and EfficacyAMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.

Knee trauma can lead to severe complications like chronic osteomyelitis, as shown in this rare paediatric case, which ...

According to Towards Healthcare, the global advanced wound care market size is calculated at USD 11.82 billion in 2025 and is ...

The Global Wound Closure Devices Market was valued at USD 14.82 billion in 2023, growing at a CAGR of 7.40% during the ...